The United Kingdom and the United States have secured a major trade agreement that will maintain zero duties on UK pharmaceutical shipments entering the US market.
The Terms of the Deal
As part of the deal, the UK has committed to raise expenditure on pharmaceuticals through the NHS. This commitment ensures that tariffs on these crucial goods will remain at nothing for a timeframe of three years.
This agreement comes after recent statements to significantly raise duties on branded pharmaceutical imports, with potential rates discussed as high as double the cost.
"This agreement with the UK bolsters the international landscape for innovative medicines and establishes long-overdue equity to American-British medicine commerce," an announcement said.
Trade Impact
Pharmaceuticals represent one of the the United Kingdom's biggest goods shipped to the America, which is clearly the primary market for leading companies like GSK and AstraZeneca.
Trade data reveal that in the year to the end of last September, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This agreement secures work, boosts capital expenditure and sets the stage for the UK to establish itself as a worldwide center for medical research," a government official remarked.
Key UK Commitments
The deal entails several specific changes from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double total NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The sum drug companies must return to the NHS to control costs will be limited at fifteen percent. Previously, repayments topped twenty percent.
Recent Tensions
The deal comes amid a ongoing tension between the pharmaceutical industry and the ministers over spending levels and approval rates.
This friction were heightened by assertions that American patients were paying a premium for the same drugs than patients in the other developed nations.
Recently, several significant manufacturing plans in the UK have been halted or abandoned, while substantial funding commitments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the last ten years.
